Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...